Cyprus · Clinical Bridge · Radiopharmaceuticals
Daughter of Helios. Pharmakeia.
Cyrcea connects novel radiopharmaceutical developers with nuclear medicine departments in Cyprus for early-phase clinical evaluation — bridging R&D innovation with first-in-human studies within the EU.
What we do
We act as the structured pathway between radiopharmaceutical innovators and accredited nuclear medicine departments — enabling Phase I studies in an EU-regulated, cost-efficient, and scientifically rigorous environment.
We provide a fully managed pathway to evaluate your novel diagnostic or therapeutic radiopharmaceuticals in Phase I clinical studies — from regulatory strategy to patient access.
We bring cutting-edge compounds to your department, handling the commercial, contractual, and coordination layer — so your clinical team can focus on science and patient care.
Novel PET and SPECT tracers for oncology, neurology, and cardiology — evaluated through structured imaging studies with rigorous biodistribution and dosimetry protocols.
Targeted radionuclide therapy compounds — including alpha and beta emitters — evaluated under GCP-compliant Phase I frameworks with full dosimetry and safety monitoring.
The model
Why Cyprus
Full EMA regulatory framework. Data generated in Cyprus is valid across all EU member states and accepted in international regulatory submissions.
Substantially lower Phase I operational costs compared to Western European hubs, without compromising scientific rigour or GCP compliance standards.
Agile national ethics and competent authority review timelines. A focused, smaller regulatory environment enables faster study initiation.
Accredited nuclear medicine departments with established PET, SPECT, and dosimetry capabilities ready for early-phase evaluation.
Gateway between Europe, the Middle East, and North Africa. Ideal for sponsors seeking EU registration while maintaining proximity to emerging markets.
Medical, regulatory, and legal infrastructure operates fully in English — minimising friction for international sponsors and reducing documentation overhead.
Get in touch
Whether you are an R&D developer with a compound ready for evaluation, or a nuclear medicine department interested in partnership — we would like to hear from you.
"Κίρκη — she who transforms. Daughter of the sun. Maker of medicines. From her island, she changed the nature of things."
— Homer, The Odyssey · Our namesake